Affordable Access

deepdyve-link
Publisher Website

Five-year analysis from phase 2 trial of "sandwich" chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.

Authors
  • Zhang, Li1, 2
  • Jiang, Ming1
  • Xie, Li3
  • Zhang, Hong3
  • Jiang, Yu1
  • Yang, Qun-pei4
  • Liu, Wei-ping4
  • Zhang, Wen-yan4
  • Zhuo, Hong-yu1
  • Li, Ping3
  • Chen, Nian-yong3
  • Zhao, Sha4
  • Wang, Feng3
  • Zou, Li-qun1
  • 1 Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China. , (China)
  • 2 Department of Oncology, Dujiangyan Medical Center, Dujiangyan, Sichuan, China. , (China)
  • 3 Radiation Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, China. , (China)
  • 4 Pathology Department, West China Hospital of Sichuan University, Chengdu, China. , (China)
Type
Published Article
Journal
Cancer Medicine
Publisher
Wiley
Publication Date
Jan 01, 2016
Volume
5
Issue
1
Pages
33–40
Identifiers
DOI: 10.1002/cam4.569
PMID: 26633585
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The "sandwich" protocol, was first proposed by us and comprised of l-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy, results in 2-year overall survival and progression-free survival rates that surpass traditional therapies for patients with newly diagnosed, stage IE-IIE, nasal type, extranodal natural killer/T-cell lymphoma. The results had been published by cancer. These patients were followed up over a median period of 67 months, for which updates and the results of prognostic factors analyses are presented. The 5-year overall survival and progress-free survival rates were both 64%. The highest rates of death occurred during the first 6 months, and between the second and third year after enrollment. The initial therapeutic response (odds ratio = 5.83; P = 0.001) and B symptoms (odds ratio = 6.13; P = 0.043) were significant prognostic factors for overall survival. However, the international prognostic index was not significant for progress-free survival and overall survival. There were no severe long-term side effects. These results indicate that the "sandwich" protocol may benefit the long-term survival of patients with newly diagnosed stage IE-IIE, nasal type, extranodal natural killer/T-cell lymphoma. However, additional studies with larger samples are required to confirm these results. This study is registered at www.Chictr.org (ChicTR-TNC-09000394). © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times